Global Myocardial Infarction Treatment Market
Global Myocardial Infarction Treatment Market

Myocardial Infarction Treatment Comprehensive Study by Type (Supportive Care {Defibrillation, Oxygen}, Medication {Anticoagulant, Antianginal, Narcotic, Beta Blocker, Statin, Ace Inhibitor}, Therapy {Cardiac Rehabilitation}, Surgery {Coronary Artery Bypass Surgery}), Application (Hospitals, Clinics, Ambulatory Services Care, Intensive Care Unit), Distribution Channel (Hospital Pharmacies, Medical Stores, Online Stores), Tests (Electrocardiogram (EKG), Physical Examination, Blood Tests {Troponin}, Echocardiogram, Radionuclide Imaging, Others) Players and Region - Global Market Outlook to 2025

Myocardial Infarction Treatment Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Mar 2020 Edition 225 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Myocardial Infarction Treatment Market Definition
Myocardial infarction is commonly known as a heart attack that occurs when a portion of the heart does not get enough oxygen supply due to the blockage of a coronary artery which helps in supplying oxygenated blood to the heart muscle. The myocardial infarction treatment involves the medication, medical procedure, surgery and therapies to prevent a heart attack or treat the blocked coronary artery. The usual cause of myocardial infarction is the formation of a blood clot which is also called a thrombus, this clot forms inside the artery that has been narrowed by atherosclerosis. The atherosclerosis is a condition where plaques (fatty deposits) build up along the inside walls of blood vessels.

The market study is broken down by Type (Supportive Care {Defibrillation, Oxygen}, Medication {Anticoagulant, Antianginal, Narcotic, Beta Blocker, Statin, Ace Inhibitor}, Therapy {Cardiac Rehabilitation} and Surgery {Coronary Artery Bypass Surgery}), by Application (Hospitals, Clinics, Ambulatory Services Care and Intensive Care Unit) and major geographies with country level splits.

Athersys, Inc. (United States), Novartis International AG (Switzerland), Bayer AG (Germany), Bristol Myers Squibb Company (United States), Merck Group (United States), Sanofi S.A. (France), Pfizer Inc. (United States), Daiichi Sankyo Company (Japan), Boehringer Ingelheim International GmbH (Germany), AstraZeneca plc (United Kingdom), ZOLL Medical Corporation (TherOx Inc.) (United States) and Miracor Medical SA (Belgium) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Myocardial Infarction Treatment market by Type, Application and Region.

On the basis of geography, the market of Myocardial Infarction Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel , the sub-segment i.e. Hospital Pharmacies will boost the Myocardial Infarction Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Tests, the sub-segment i.e. Electrocardiogram (EKG) will boost the Myocardial Infarction Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

On 4th April 2019, TherOx, Inc. announced that the US Food and Drug (FDA) granted premarket approval for its SuperSaturated Oxygen (SSO2) therapy. It provides interventional cardiologists with the first and only FDA approved treatment beyond percutaneous coronary intervention (PCI) to significantly reduce muscle damage in heart attack patients.


Market Trend
  • Sudden Increase of Myocardial Infarction Treatment in Young Adults
  • Introduction of Wireless Myocardial Infarction Monitoring Devices for Treatment

Market Drivers
  • The Rising Prevalence of Cardiovascular Disease Among the Geriatric Population
  • High Blood Pressure and Cholesterol Problems in People

Opportunities
  • Awareness about Myocardial Infarction Treatment Around the World
  • Surging Advancements in Devices and Drugs Used in Myocardial Infarction Treatment

Restraints
  • Complexities and Complications Involved in Myocardial Infarction Treatment

Challenges
  • Less Reach of Myocardial Infarction Treatment in Rural Region
  • Adherence to Regulatory Guidelines on Myocardial Infarction Treatment


Key Target Audience
Myocardial Infarction Treatment Providers, Myocardial Infarction Treatment Device Manufacturers, Research and Development Institutes, Financial Institutions and Venture Capital, Regulatory Bodies, Hospital, Industry Associations and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Supportive Care {Defibrillation, Oxygen}
  • Medication {Anticoagulant, Antianginal, Narcotic, Beta Blocker, Statin, Ace Inhibitor}
  • Therapy {Cardiac Rehabilitation}
  • Surgery {Coronary Artery Bypass Surgery}
By Application
  • Hospitals
  • Clinics
  • Ambulatory Services Care
  • Intensive Care Unit
By Distribution Channel
  • Hospital Pharmacies
  • Medical Stores
  • Online Stores

By Tests
  • Electrocardiogram (EKG)
  • Physical Examination
  • Blood Tests {Troponin}
  • Echocardiogram
  • Radionuclide Imaging
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Prevalence of Cardiovascular Disease Among the Geriatric Population
      • 3.2.2. High Blood Pressure and Cholesterol Problems in People
    • 3.3. Market Challenges
      • 3.3.1. Less Reach of Myocardial Infarction Treatment in Rural Region
      • 3.3.2. Adherence to Regulatory Guidelines on Myocardial Infarction Treatment
    • 3.4. Market Trends
      • 3.4.1. Sudden Increase of Myocardial Infarction Treatment in Young Adults
      • 3.4.2. Introduction of Wireless Myocardial Infarction Monitoring Devices for Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Myocardial Infarction Treatment, by Type, Application, Distribution Channel , Tests and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Myocardial Infarction Treatment (Value)
      • 5.2.1. Global Myocardial Infarction Treatment by: Type (Value)
        • 5.2.1.1. Supportive Care {Defibrillation, Oxygen}
        • 5.2.1.2. Medication {Anticoagulant, Antianginal, Narcotic, Beta Blocker, Statin, Ace Inhibitor}
        • 5.2.1.3. Therapy {Cardiac Rehabilitation}
        • 5.2.1.4. Surgery {Coronary Artery Bypass Surgery}
      • 5.2.2. Global Myocardial Infarction Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Services Care
        • 5.2.2.4. Intensive Care Unit
      • 5.2.3. Global Myocardial Infarction Treatment by: Tests (Value)
        • 5.2.3.1. Electrocardiogram (EKG)
        • 5.2.3.2. Physical Examination
        • 5.2.3.3. Blood Tests {Troponin}
        • 5.2.3.4. Echocardiogram
        • 5.2.3.5. Radionuclide Imaging
        • 5.2.3.6. Others
      • 5.2.4. Global Myocardial Infarction Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Myocardial Infarction Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Athersys, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol Myers Squibb Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck Group (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi S.A. (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Daiichi Sankyo Company (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Boehringer Ingelheim International GmbH (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. ZOLL Medical Corporation (TherOx Inc.) (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Miracor Medical SA (Belgium)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Myocardial Infarction Treatment Sale, by Type, Application, Distribution Channel , Tests and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Myocardial Infarction Treatment (Value)
      • 7.2.1. Global Myocardial Infarction Treatment by: Type (Value)
        • 7.2.1.1. Supportive Care {Defibrillation, Oxygen}
        • 7.2.1.2. Medication {Anticoagulant, Antianginal, Narcotic, Beta Blocker, Statin, Ace Inhibitor}
        • 7.2.1.3. Therapy {Cardiac Rehabilitation}
        • 7.2.1.4. Surgery {Coronary Artery Bypass Surgery}
      • 7.2.2. Global Myocardial Infarction Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Services Care
        • 7.2.2.4. Intensive Care Unit
      • 7.2.3. Global Myocardial Infarction Treatment by: Tests (Value)
        • 7.2.3.1. Electrocardiogram (EKG)
        • 7.2.3.2. Physical Examination
        • 7.2.3.3. Blood Tests {Troponin}
        • 7.2.3.4. Echocardiogram
        • 7.2.3.5. Radionuclide Imaging
        • 7.2.3.6. Others
      • 7.2.4. Global Myocardial Infarction Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Myocardial Infarction Treatment: by Type(USD Million)
  • Table 2. Myocardial Infarction Treatment Supportive Care {Defibrillation, Oxygen} , by Region USD Million (2014-2019)
  • Table 3. Myocardial Infarction Treatment Medication {Anticoagulant, Antianginal, Narcotic, Beta Blocker, Statin, Ace Inhibitor} , by Region USD Million (2014-2019)
  • Table 4. Myocardial Infarction Treatment Therapy {Cardiac Rehabilitation} , by Region USD Million (2014-2019)
  • Table 5. Myocardial Infarction Treatment Surgery {Coronary Artery Bypass Surgery} , by Region USD Million (2014-2019)
  • Table 6. Myocardial Infarction Treatment: by Application(USD Million)
  • Table 7. Myocardial Infarction Treatment Hospitals , by Region USD Million (2014-2019)
  • Table 8. Myocardial Infarction Treatment Clinics , by Region USD Million (2014-2019)
  • Table 9. Myocardial Infarction Treatment Ambulatory Services Care , by Region USD Million (2014-2019)
  • Table 10. Myocardial Infarction Treatment Intensive Care Unit , by Region USD Million (2014-2019)
  • Table 11. Myocardial Infarction Treatment: by Tests(USD Million)
  • Table 12. Myocardial Infarction Treatment Electrocardiogram (EKG) , by Region USD Million (2014-2019)
  • Table 13. Myocardial Infarction Treatment Physical Examination , by Region USD Million (2014-2019)
  • Table 14. Myocardial Infarction Treatment Blood Tests {Troponin} , by Region USD Million (2014-2019)
  • Table 15. Myocardial Infarction Treatment Echocardiogram , by Region USD Million (2014-2019)
  • Table 16. Myocardial Infarction Treatment Radionuclide Imaging , by Region USD Million (2014-2019)
  • Table 17. Myocardial Infarction Treatment Others , by Region USD Million (2014-2019)
  • Table 18. South America Myocardial Infarction Treatment, by Country USD Million (2014-2019)
  • Table 19. South America Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 20. South America Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 21. South America Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 22. South America Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 23. Brazil Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 24. Brazil Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 25. Brazil Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 26. Brazil Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 27. Argentina Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 28. Argentina Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 29. Argentina Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 30. Argentina Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 31. Rest of South America Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 32. Rest of South America Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 33. Rest of South America Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 34. Rest of South America Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 35. Asia Pacific Myocardial Infarction Treatment, by Country USD Million (2014-2019)
  • Table 36. Asia Pacific Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 37. Asia Pacific Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 38. Asia Pacific Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 39. Asia Pacific Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 40. China Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 41. China Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 42. China Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 43. China Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 44. Japan Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 45. Japan Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 46. Japan Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 47. Japan Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 48. India Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 49. India Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 50. India Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 51. India Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 52. South Korea Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 53. South Korea Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 54. South Korea Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 55. South Korea Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 56. Taiwan Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 57. Taiwan Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 58. Taiwan Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 59. Taiwan Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 60. Australia Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 61. Australia Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 62. Australia Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 63. Australia Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 68. Europe Myocardial Infarction Treatment, by Country USD Million (2014-2019)
  • Table 69. Europe Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 70. Europe Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 71. Europe Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 72. Europe Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 73. Germany Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 74. Germany Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 75. Germany Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 76. Germany Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 77. France Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 78. France Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 79. France Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 80. France Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 81. Italy Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 82. Italy Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 83. Italy Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 84. Italy Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 85. United Kingdom Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 86. United Kingdom Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 87. United Kingdom Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 88. United Kingdom Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 89. Netherlands Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 90. Netherlands Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 91. Netherlands Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 92. Netherlands Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 93. Rest of Europe Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 94. Rest of Europe Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 95. Rest of Europe Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 96. Rest of Europe Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 97. MEA Myocardial Infarction Treatment, by Country USD Million (2014-2019)
  • Table 98. MEA Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 99. MEA Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 100. MEA Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 101. MEA Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 102. Middle East Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 103. Middle East Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 104. Middle East Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 105. Middle East Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 106. Africa Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 107. Africa Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 108. Africa Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 109. Africa Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 110. North America Myocardial Infarction Treatment, by Country USD Million (2014-2019)
  • Table 111. North America Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 112. North America Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 113. North America Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 114. North America Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 115. United States Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 116. United States Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 117. United States Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 118. United States Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 119. Canada Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 120. Canada Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 121. Canada Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 122. Canada Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 123. Mexico Myocardial Infarction Treatment, by Type USD Million (2014-2019)
  • Table 124. Mexico Myocardial Infarction Treatment, by Application USD Million (2014-2019)
  • Table 125. Mexico Myocardial Infarction Treatment, by Distribution Channel USD Million (2014-2019)
  • Table 126. Mexico Myocardial Infarction Treatment, by Tests USD Million (2014-2019)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Myocardial Infarction Treatment: by Type(USD Million)
  • Table 140. Myocardial Infarction Treatment Supportive Care {Defibrillation, Oxygen} , by Region USD Million (2020-2025)
  • Table 141. Myocardial Infarction Treatment Medication {Anticoagulant, Antianginal, Narcotic, Beta Blocker, Statin, Ace Inhibitor} , by Region USD Million (2020-2025)
  • Table 142. Myocardial Infarction Treatment Therapy {Cardiac Rehabilitation} , by Region USD Million (2020-2025)
  • Table 143. Myocardial Infarction Treatment Surgery {Coronary Artery Bypass Surgery} , by Region USD Million (2020-2025)
  • Table 144. Myocardial Infarction Treatment: by Application(USD Million)
  • Table 145. Myocardial Infarction Treatment Hospitals , by Region USD Million (2020-2025)
  • Table 146. Myocardial Infarction Treatment Clinics , by Region USD Million (2020-2025)
  • Table 147. Myocardial Infarction Treatment Ambulatory Services Care , by Region USD Million (2020-2025)
  • Table 148. Myocardial Infarction Treatment Intensive Care Unit , by Region USD Million (2020-2025)
  • Table 149. Myocardial Infarction Treatment: by Tests(USD Million)
  • Table 150. Myocardial Infarction Treatment Electrocardiogram (EKG) , by Region USD Million (2020-2025)
  • Table 151. Myocardial Infarction Treatment Physical Examination , by Region USD Million (2020-2025)
  • Table 152. Myocardial Infarction Treatment Blood Tests {Troponin} , by Region USD Million (2020-2025)
  • Table 153. Myocardial Infarction Treatment Echocardiogram , by Region USD Million (2020-2025)
  • Table 154. Myocardial Infarction Treatment Radionuclide Imaging , by Region USD Million (2020-2025)
  • Table 155. Myocardial Infarction Treatment Others , by Region USD Million (2020-2025)
  • Table 156. South America Myocardial Infarction Treatment, by Country USD Million (2020-2025)
  • Table 157. South America Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 158. South America Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 159. South America Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 160. South America Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 161. Brazil Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 162. Brazil Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 163. Brazil Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 164. Brazil Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 165. Argentina Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 166. Argentina Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 167. Argentina Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 168. Argentina Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 169. Rest of South America Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 170. Rest of South America Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 171. Rest of South America Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 172. Rest of South America Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 173. Asia Pacific Myocardial Infarction Treatment, by Country USD Million (2020-2025)
  • Table 174. Asia Pacific Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 175. Asia Pacific Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 176. Asia Pacific Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 177. Asia Pacific Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 178. China Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 179. China Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 180. China Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 181. China Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 182. Japan Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 183. Japan Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 184. Japan Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 185. Japan Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 186. India Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 187. India Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 188. India Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 189. India Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 190. South Korea Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 191. South Korea Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 192. South Korea Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 193. South Korea Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 194. Taiwan Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 195. Taiwan Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 196. Taiwan Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 197. Taiwan Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 198. Australia Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 199. Australia Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 200. Australia Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 201. Australia Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 202. Rest of Asia-Pacific Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 203. Rest of Asia-Pacific Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 204. Rest of Asia-Pacific Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 205. Rest of Asia-Pacific Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 206. Europe Myocardial Infarction Treatment, by Country USD Million (2020-2025)
  • Table 207. Europe Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 208. Europe Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 209. Europe Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 210. Europe Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 211. Germany Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 212. Germany Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 213. Germany Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 214. Germany Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 215. France Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 216. France Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 217. France Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 218. France Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 219. Italy Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 220. Italy Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 221. Italy Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 222. Italy Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 223. United Kingdom Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 224. United Kingdom Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 225. United Kingdom Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 226. United Kingdom Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 227. Netherlands Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 228. Netherlands Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 229. Netherlands Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 230. Netherlands Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 231. Rest of Europe Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 232. Rest of Europe Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 233. Rest of Europe Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 234. Rest of Europe Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 235. MEA Myocardial Infarction Treatment, by Country USD Million (2020-2025)
  • Table 236. MEA Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 237. MEA Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 238. MEA Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 239. MEA Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 240. Middle East Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 241. Middle East Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 242. Middle East Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 243. Middle East Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 244. Africa Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 245. Africa Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 246. Africa Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 247. Africa Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 248. North America Myocardial Infarction Treatment, by Country USD Million (2020-2025)
  • Table 249. North America Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 250. North America Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 251. North America Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 252. North America Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 253. United States Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 254. United States Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 255. United States Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 256. United States Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 257. Canada Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 258. Canada Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 259. Canada Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 260. Canada Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 261. Mexico Myocardial Infarction Treatment, by Type USD Million (2020-2025)
  • Table 262. Mexico Myocardial Infarction Treatment, by Application USD Million (2020-2025)
  • Table 263. Mexico Myocardial Infarction Treatment, by Distribution Channel USD Million (2020-2025)
  • Table 264. Mexico Myocardial Infarction Treatment, by Tests USD Million (2020-2025)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Myocardial Infarction Treatment: by Type USD Million (2014-2019)
  • Figure 5. Global Myocardial Infarction Treatment: by Application USD Million (2014-2019)
  • Figure 6. Global Myocardial Infarction Treatment: by Tests USD Million (2014-2019)
  • Figure 7. South America Myocardial Infarction Treatment Share (%), by Country
  • Figure 8. Asia Pacific Myocardial Infarction Treatment Share (%), by Country
  • Figure 9. Europe Myocardial Infarction Treatment Share (%), by Country
  • Figure 10. MEA Myocardial Infarction Treatment Share (%), by Country
  • Figure 11. North America Myocardial Infarction Treatment Share (%), by Country
  • Figure 12. Global Myocardial Infarction Treatment share by Players 2019 (%)
  • Figure 13. Global Myocardial Infarction Treatment share by Players (Top 3) 2019(%)
  • Figure 14. Global Myocardial Infarction Treatment share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Athersys, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Athersys, Inc. (United States) Revenue: by Geography 2019
  • Figure 18. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis International AG (Switzerland) Revenue: by Geography 2019
  • Figure 20. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Bayer AG (Germany) Revenue: by Geography 2019
  • Figure 22. Bristol Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Bristol Myers Squibb Company (United States) Revenue: by Geography 2019
  • Figure 24. Merck Group (United States) Revenue, Net Income and Gross profit
  • Figure 25. Merck Group (United States) Revenue: by Geography 2019
  • Figure 26. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 27. Sanofi S.A. (France) Revenue: by Geography 2019
  • Figure 28. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 30. Daiichi Sankyo Company (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Daiichi Sankyo Company (Japan) Revenue: by Geography 2019
  • Figure 32. Boehringer Ingelheim International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Boehringer Ingelheim International GmbH (Germany) Revenue: by Geography 2019
  • Figure 34. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. AstraZeneca plc (United Kingdom) Revenue: by Geography 2019
  • Figure 36. ZOLL Medical Corporation (TherOx Inc.) (United States) Revenue, Net Income and Gross profit
  • Figure 37. ZOLL Medical Corporation (TherOx Inc.) (United States) Revenue: by Geography 2019
  • Figure 38. Miracor Medical SA (Belgium) Revenue, Net Income and Gross profit
  • Figure 39. Miracor Medical SA (Belgium) Revenue: by Geography 2019
  • Figure 40. Global Myocardial Infarction Treatment: by Type USD Million (2020-2025)
  • Figure 41. Global Myocardial Infarction Treatment: by Application USD Million (2020-2025)
  • Figure 42. Global Myocardial Infarction Treatment: by Tests USD Million (2020-2025)
  • Figure 43. South America Myocardial Infarction Treatment Share (%), by Country
  • Figure 44. Asia Pacific Myocardial Infarction Treatment Share (%), by Country
  • Figure 45. Europe Myocardial Infarction Treatment Share (%), by Country
  • Figure 46. MEA Myocardial Infarction Treatment Share (%), by Country
  • Figure 47. North America Myocardial Infarction Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Athersys, Inc. (United States)
  • Novartis International AG (Switzerland)
  • Bayer AG (Germany)
  • Bristol Myers Squibb Company (United States)
  • Merck Group (United States)
  • Sanofi S.A. (France)
  • Pfizer Inc. (United States)
  • Daiichi Sankyo Company (Japan)
  • Boehringer Ingelheim International GmbH (Germany)
  • AstraZeneca plc (United Kingdom)
  • ZOLL Medical Corporation (TherOx Inc.) (United States)
  • Miracor Medical SA (Belgium)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation